CG Oncology/$CGON
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CG Oncology
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Ticker
$CGON
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
113
ISIN
US1569441009
Website
CG Oncology Metrics
BasicAdvanced
$2B
-
-$1.51
-
-
Price and volume
Market cap
$2B
52-week high
$39.50
52-week low
$14.80
Average daily volume
1.1M
Financial strength
Current ratio
30.969
Quick ratio
30.42
Long term debt to equity
0.111
Total debt to equity
0.147
Profitability
EBITDA (TTM)
-134.349
Gross margin (TTM)
-13,851.51%
Net profit margin (TTM)
-15,945.17%
Operating margin (TTM)
-20,302.27%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-12.85%
Return on equity (TTM)
-16.57%
Valuation
Price to revenue (TTM)
2,770.106
Price to book
2.84
Price to tangible book (TTM)
2.84
Price to free cash flow (TTM)
-22.304
Free cash flow yield (TTM)
-4.48%
Free cash flow per share (TTM)
-117.83%
Growth
Revenue change (TTM)
22.82%
Earnings per share change (TTM)
-68.35%
What the Analysts think about CG Oncology
Analyst ratings (Buy, Hold, Sell) for CG Oncology stock.
Bulls say / Bears say
CG Oncology's experimental immunotherapy drug, cretostimogene, demonstrated a 75% complete remission rate in bladder cancer patients unresponsive to current therapies, with many remaining cancer-free beyond two years. (reuters.com)
The company successfully raised $380 million in its Nasdaq IPO, pricing shares above the marketed range, indicating strong investor confidence. (bloomberg.com)
Goldman Sachs reaffirmed its 'Buy' rating on CG Oncology, citing limited downside amid new data, with a consistent price target of $52.00. (investing.com)
CG Oncology reported a net loss of $20.4 million in Q3 2024, an increase from $17.5 million in Q3 2023, indicating rising operational expenses. (stocktitan.net)
Research and development expenses surged by 67.5% year-over-year to $19.6 million, potentially impacting short-term profitability. (stocktitan.net)
General and administrative expenses significantly increased to $8.7 million from $2.3 million year-over-year, reflecting higher operational costs. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
CG Oncology Financial Performance
Revenues and expenses
CG Oncology Earnings Performance
Company profitability
CG Oncology News
AllArticlesVideos
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewsWire·2 weeks ago
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
GlobeNewsWire·1 month ago
CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why
Benzinga·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CG Oncology stock?
CG Oncology (CGON) has a market cap of $2B as of June 20, 2025.
What is the P/E ratio for CG Oncology stock?
The price to earnings (P/E) ratio for CG Oncology (CGON) stock is 0 as of June 20, 2025.
Does CG Oncology stock pay dividends?
No, CG Oncology (CGON) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next CG Oncology dividend payment date?
CG Oncology (CGON) stock does not pay dividends to its shareholders.
What is the beta indicator for CG Oncology?
CG Oncology (CGON) does not currently have a Beta indicator.